📊 PCRX Key Takeaways
Is Pacira BioSciences, Inc. (PCRX) a Good Investment?
Pacira BioSciences exhibits severely compressed profitability with 1.6% net margins and minimal ROE/ROA, indicating fundamental operational challenges despite adequate revenue base. The company carries substantial leverage ($367.7M long-term debt) with tight interest coverage (1.9x), leaving little margin for error; while free cash flow is positive, the tight debt service burden limits financial flexibility.
Pacira BioSciences, Inc. Key Strengths (PCRX)
- Strong liquidity position with 4.73x current ratio and $144.3M cash
- Positive free cash flow generation of $23M with 12.9% FCF margin despite low net profitability
- Low capital intensity (2.7M capex) indicates relatively asset-light operations
PCRX Stock Risks: Pacira BioSciences, Inc. Investment Risks
- Critically low profitability: 1.6% net margin and 3.9% operating margin insufficient for a pharmaceutical company
- Severe capital inefficiency with 0.4% ROE and 0.2% ROA indicating value destruction
- Elevated leverage risk: 1.9x interest coverage is dangerously tight; high debt-to-equity of 0.56x limits strategic flexibility
- Anemic revenue growth at 3.6% YoY is inadequate for sustainable debt service
Key Metrics to Watch
- Operating margin trend and path to 10%+ profitability
- Interest coverage ratio - must improve above 2.5x to reduce refinancing risk
- Revenue growth acceleration above 5% to support debt burden
Pacira BioSciences, Inc. (PCRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.73x current ratio provides a solid financial cushion.
PCRX Profit Margin, ROE & Profitability Analysis
PCRX vs Healthcare Sector: How Pacira BioSciences, Inc. Compares
How Pacira BioSciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pacira BioSciences, Inc. Stock Overvalued? PCRX Valuation Analysis 2026
Based on fundamental analysis, Pacira BioSciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pacira BioSciences, Inc. Balance Sheet: PCRX Debt, Cash & Liquidity
PCRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pacira BioSciences, Inc.'s revenue has grown significantly by 70% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.89 reflects profitable operations.
PCRX Revenue Growth, EPS Growth & YoY Performance
PCRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $168.9M | $2.9M | $0.07 |
| Q3 2025 | $168.6M | $5.4M | $0.12 |
| Q2 2025 | $178.0M | -$35.0K | $0.00 |
| Q1 2025 | $167.1M | $4.8M | $0.10 |
| Q3 2024 | $163.9M | $10.9M | $0.23 |
| Q2 2024 | $169.5M | $6.2M | $0.13 |
| Q1 2024 | $160.3M | $9.0M | $0.19 |
| Q3 2023 | $163.9M | -$693.0K | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pacira BioSciences, Inc. Dividends, Buybacks & Capital Allocation
PCRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pacira BioSciences, Inc. (CIK: 0001396814)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PCRX
What is the AI rating for PCRX?
Pacira BioSciences, Inc. (PCRX) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCRX's key strengths?
Claude: Strong liquidity position with 4.73x current ratio and $144.3M cash. Positive free cash flow generation of $23M with 12.9% FCF margin despite low net profitability.
What are the risks of investing in PCRX?
Claude: Critically low profitability: 1.6% net margin and 3.9% operating margin insufficient for a pharmaceutical company. Severe capital inefficiency with 0.4% ROE and 0.2% ROA indicating value destruction.
What is PCRX's revenue and growth?
Pacira BioSciences, Inc. reported revenue of $177.4M.
Does PCRX pay dividends?
Pacira BioSciences, Inc. does not currently pay dividends.
Where can I find PCRX SEC filings?
Official SEC filings for Pacira BioSciences, Inc. (CIK: 0001396814) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCRX's EPS?
Pacira BioSciences, Inc. has a diluted EPS of $0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PCRX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pacira BioSciences, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PCRX stock overvalued or undervalued?
Valuation metrics for PCRX: ROE of 0.4% (sector avg: 15%), net margin of 1.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PCRX's AI grade for 2026?
Our dual AI analysis gives Pacira BioSciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCRX's free cash flow?
Pacira BioSciences, Inc.'s operating cash flow is $25.7M, with capital expenditures of $2.7M. FCF margin is 12.9%.
How does PCRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.6% (avg: 12%), ROE 0.4% (avg: 15%), current ratio 4.73 (avg: 2).